文献速递肺结节与肺癌

肺癌筛查风险预测模型:系统综述与Meta回归

Risk prediction for lung cancer screening: a systematic review and meta-regression
RSS 订阅 · PubMed 高证据 · 肺结节与肺癌筛查 · 2026-07-08

该研究系统检索2020年1月至2026年1月文献,纳入91个肺癌筛查风险预测模型,其中56个用于筛查人群选择、35个用于筛查后肺结节分类。模型区分度从中等(AUC约0.70)到优秀(>0.90),含生物标志物和影像增强的模型常表现更优,但校准报告不一致且不足半数进行外部验证。多数模型尚不成熟,暂不适合临床采用。

要点

  • 91个肺癌筛查风险模型区分度不等,含生物标志物或影像增强者常更优。
  • 校准报告不一致,不足半数模型经过外部验证,临床适用性不确定。
  • 未来应优先外部验证、更新和比较评估现有模型,而非继续开发新模型。

核心结论

  • 多数肺癌筛查风险预测模型区分度有前景,但成熟度不足,暂不适合临床采用。
  • 未来研究应优先外部验证、更新和比较评估现有模型,并开展前瞻性实施研究。

研究设计与样本

  • 系统综述与探索性Meta回归,检索Embase和Medline(2020年1月至2026年1月)。
  • 从2462条记录中纳入91项研究,56个模型用于筛查选择,35个用于筛查后结节分类。

主要发现

  • 回归模型占主导,机器学习方法日益常见。
  • 模型区分度从中等(AUC约0.70)到优秀(>0.90),含生物标志物和影像增强的模型常优于不含者。
  • 校准报告不一致,不足半数模型经过外部验证。

关键数值与推荐

  • 区分度AUC约0.70为中等,>0.90为优秀。
  • 56个筛查选择模型中30个包含生物标志物。

临床怎么用

  • 现有模型暂不宜直接用于临床筛查决策,选用时需关注其外部验证情况。

局限性

  • 校准报告不一致,不足半数模型经过外部验证,原始研究外性能不确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Eur Respir Rev. 2026 Jul 8;35(181):250295. doi: 10.1183/16000617.0295-2025. Print 2026 Jul. ABSTRACT BACKGROUND: Lung cancer (LC) remains the deadliest cancer, often diagnosed at advanced stages. Screening reduces mortality in high-risk individuals. Eligibility criteria in European and US screening guidelines have recently expanded. Therefore, we conducted an updated systematic review of risk-based models for identifying candidates for low-dose computed tomography screening and post-screening nodule classification. METHODS: We systematically searched Embase and Medline (January 2020-January 2026), identifying studies proposing new risk models in the context of LC screening. We separated models by pre- and post-screening risk stratification. Data extraction included study design, population, model type, risk horizon and model performance metrics. We performed an exploratory meta-regression of areas under the curve (AUCs) to assess whether sample size, model type, validation type and inclusion of biomarkers were associated with performance. RESULTS: Of 2462 records, 91 were included. 56 models were for screening selection (30 included biomarkers) and 35 for post-screening nodule classification. Regression-based models predominated, though machine-learning approaches were increasingly common. Discrimination ranged from moderate (AUC∼0.70) to excellent (>0.90), with biomarker and imaging-enhanced models often outperforming models without. Calibration was inconsistently reported and fewer than half underwent external validation. CONCLUSION: We identified 91 risk prediction models for LC, developed after 2020. Although many demonstrated promising discrimination across both screening selection and post-screening management, most remain insufficiently mature for clinical adoption, as their performance and practical value outside the original study setting are uncertain. Future work should prioritise external validation, updating and comparative evaluation of existing models, and prospective implementation studies rather than continued development of additional models. PMID: 42419775 | PMC: PMC13343208 | DOI: 10.1183/16000617.0295-2025

来源:PubMed 高证据 · 肺结节与肺癌筛查,查看原文。版权归原作者所有。

引用

  1. PubMed 高证据 · 肺结节与肺癌筛查:Risk prediction for lung cancer screening: a systematic review and meta-regression

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。